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Dear Editor,
β
-thalassemia  major  is  a  hereditary  anemia, 
characterized  by  a  genetic  deficiency  in 
the synthesis of the β-globin chain (1). The main 
complication  of  the  multiple  blood  transfusions 
to  these  patients  is  iron  overload  and  the 
deposition of iron in various organs, such as the 
reticuloendothelial system, the liver, the heart and 
the endocrine glands (2).
Chelators  also  have  various  side  effects  on 
multiple  organs  in  thalassemic  patients,  besides 
iron  overload.  Deferoxamin  (DFO)  which  is 
the chelating agent most widely used for the last 
30  years,  mainly  affects  the  optic,  auditory  and 
skeletal systems (3). The effective management of 
thalassemic  patients,  especially  children,  requires 
monitoring  of  the  toxic  effects  of  iron  overload 
versus chelation therapy.
The most reliable method of calculating body iron 
stores is the biochemical or histochemical assessment 
of iron in a liver biopsy specimen. Since liver biopsy 
is an invasive procedure, attempts have been made 
to  use  imaging  for  detection  and  quantification 
of  liver  iron  content  (4-7).  Magnetic  resonance 
imaging (MRI) is a technique for the diagnosis of 
hemochromatosis. Many investigators have shown 
that hepatic T2 relaxation or intensity ratios in MR 
images have a significant correlation with hepatic 
iron content (8-11).
In this study, we have evaluated the correlation of 
the hemochromatosis grades in liver MRIs and liver 
biopsies to evaluate the precision of liver MRIs in 
grading hemochromatosis. This double-blind cross-
sectional study was conducted between January 2007 
and April 2008 at the Hematology Research Center, 
Shiraz University of Medical Sciences.
Twenty-eight  blood  transfusion-dependent 
thalassemia  major  patients  were  involved  in  this 
double-blind  cross-sectional  study.  Thalassemia 
major was determined in these patients by a complete 
blood count (CBC) and hemoglobin electrophoresis. 
Patients were selected from a population that had had 
liver biopsies performed on them for various purposes. 
The exclusion criteria for this study were acute or 
chronic viral hepatitis and any kind of infection found 
in physical examinations. 
After  obtaining  the  patients’  written  informed 
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consent,  liver  MRIs  (Philips  1.5  T-gyro  scan, 
Netherlands) were performed on the patients, and T1 
and T2 signal intensity in the liver was assessed at 3 
points. The average of the intensities was assigned as 
the mean liver signal intensity of the patient. These 
results were compared with the results of the control 
group, which were MR images of 4 non-thalassemic 
healthy subjects with normal liver function tests by an 
expert radiologist who was blinded to the pathologic 
assessments of the patients.
Liver  biopsy  slides  were  evaluated  by  an  expert 
pathologist who was blinded to the study, and were 
graded into categories of mild, moderate and severe 
hemochromatosis.  Histopathologic  evaluation  of 
liver biopsy slides by semiquantitative assessment of 
stored tissue iron revealed mild hemochromatosis in 
1 patient (3.5%), moderate hemochromatosis in 11 
patients (39.2%) and severe hemochromatosis in 16 
patients (57.1%).
The results of MRI evaluation and comparison of 
liver signal intensities in the patients and the control 
group revealed 4 (14.2%) mild, 7 (25.0%) moderate 
and 17 (60.8%) severe hemochromatosis. Spearman’s 
rho test confirmed the significant correlation of MRI 
and liver biopsy evaluation of hemochromatosis (P < 
0.001).
In 22 of 28 patients (78.5%), the MRI and liver 
biopsy results were in agreement with each other. In 
6 other cases (21.5%), the grade of hemochromatosis 
was  higher  on  liver  biopsy  evaluation.  There  was 
also  a  strong  correlation  between  the  grading  of 
hemochromatosis by MRI and by serum ferritin level 
(P = 0.000).
Considering  the  fact  that  liver  biopsy  is  very 
invasive, and that many patients refuse to submit to 
this procedure, we have shown that grading of liver 
hemochromatosis by MRI is significantly correlated 
with grading of hemochromatosis by liver biopsy (P < 
0.001). Comparing the histopathologic and radiologic 
results showed that an MRI is more accurate for the 
diagnosis  and  grading  of  liver  iron  deposition  in 
severe hemochromatosis patients.There is also strong 
agreement  between  serum  ferritin  and  the  grading 
of the liver by MRI. Although serum ferritin is not 
a  suitable  marker  for  assessing  hemochromatosis, 
and multiple factors like infection and inflammation 
affect it, we have found a strong correlation between 
serum ferritin and the grading of hemochromatosis 
by MRI. 
This means that in place of an invasive procedure 
like a liver biopsy, an MRI can be useful in monitoring 
iron  overload  in  thalassemia  major  patients.  More 
studies with larger sample sizes are needed to support 
our results. However, these results are in agreement 
with the results of previous studies (4-7, 12).
References
1.  Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 
2005;353(11):1135-46.
2.  Gabutti V, Piga A, Sacchetti L, et al. Quality of life and 
life expectancy in thalassemic patients with complications. 
Prog Clin Biol Res. 1989;309:35-41.
3.  Porter  JB,  Davis  BA.  Monitoring  chelation  therapy  to 
achieve optimal outcome in the treatment of thalassaemia. 
Best Pract Res Clin Haematol. 2002;15(2):329-68.
4.  Gandon  Y,  Olivie  D,  Guyader  D,  et  al.  Non-invasive 
assessment  of  hepatic  iron  stores  by  MRI.  Lancet. 
2004;363(9406):357-62.
5.  Wood  JC.  Magnetic  resonance  imaging  measurement  of 
iron overload. Curr Opin Hematol. 2007;14(3):183-90.
6.  Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: 
diagnosis and quantification of liver iron with gradient-echo 
MR imaging. Radiology. 1994;193(2):533-8.
7.  Ernst O, Sergent G, Bonvarlet P, Canva-Delcambre V, Paris 
JC,  L’Hermine  C.  Hepatic  iron  overload:  diagnosis  and 
quantification  with  MR  imaging.  AJR  Am  J  Roentgenol. 
1997;168(5):1205-8.
8.  Bonetti MG, Castriota-Scanderbeg A, Criconia GM, et al. 
Hepatic iron overload in thalassemic patients: proposal and 
validation of an MRI method of assessment. Pediatr Radiol. 
1996;26(9):650-6.
9.  Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance 
imaging  and  spectroscopy  of  hepatic  iron  overload. 
Radiology. 1985;154(1):137-42.
10. Ooi GC, Khong PL, Chan GC, et al. Magnetic resonance 
screening  of  iron  status  in  transfusion-dependent  beta-
thalassaemia patients. Br J Haematol. 2004;124(3):385-90.
11. Papakonstantinou  O,  Ladis  V,  Kostaridou  S,  et  al.  The 
pancreas in beta-thalassemia major: MR imaging features 
and correlation with iron stores and glucose disturbances. 
Eur Radiol. 2007;17(6):1535-43.
12. Rocchi E, Cassanelli M, Borghi A, et al. Magnetic resonance 
imaging and different levels of iron overload in chronic liver 
disease. Hepatology. 1993;17(6):997-1002.